Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions

Fineline Cube May 22, 2026
Company Deals

Johnson & Johnson Partners with Abu Dhabi DOH to Launch Global Surgical Intelligence Network Powered by Polyphonic Platform

Fineline Cube May 22, 2026
Company Deals

Eli Lilly Acquires Engage Biologics for $202M to Bolster Genetic Medicines Portfolio with Tethosome Platform

Fineline Cube May 22, 2026
Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Fineline Cube May 21, 2026
Company Deals

Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio

Fineline Cube May 21, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Allergan Aesthetics Secures CHMP Positive Opinion for Boey (TrenibotulinumtoxinE) in Glabellar Lines Treatment Across European Economic Area

Fineline Cube May 23, 2026
Company Drug

Lupeng Pharma Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Fourth-Gen BTK Inhibitor Rocbrutinib vs. Pirtobrutinib

Fineline Cube May 23, 2026
Company

Boston Scientific Posts Strong Q4 and Full-Year 2024 Results

Fineline Cube Feb 7, 2025

Boston Scientific Corporation (NYSE: BSX) released its Q4 and full-year 2024 financial report, showing robust...

Company Deals

Vigonvita Life Sciences Files for IPO on Hong Kong Stock Exchange

Fineline Cube Feb 7, 2025

Suzhou-based Vigonvita Life Sciences Co., Ltd. has submitted an initial public offering (IPO) filing to...

Policy / Regulatory

NHSA Regulates DRG/DIP Payment Methods Under ‘1+3+N’ System

Fineline Cube Feb 7, 2025

The National Healthcare Security Administration (NHSA) has released a set of regulations aimed at improving...

Policy / Regulatory

China’s NHSA and MoF Push for DRG/DIP Payment Reforms by 2025

Fineline Cube Feb 7, 2025

The National Healthcare Security Administration (NHSA) and the Ministry of Finance (MoF) have jointly released...

Company Drug

Sino Biopharmaceutical’s Tulobuterol Patch Gains NMPA Approval

Fineline Cube Feb 7, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its subsidiary Beijing Tide Pharmaceutical Co., Ltd...

Company

Regeneron’s Q4 Financials Show 10% Revenue Growth, Driven by Eylea and Libtayo

Fineline Cube Feb 7, 2025

US-based biopharmaceutical company Regeneron (NASDAQ: REGN) released its Q4 2024 financial report, showing revenues up...

Company

AstraZeneca’s 2024 Financials Beat Expectations with 21% Revenue Growth

Fineline Cube Feb 7, 2025

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) reported total revenues of USD 54.07 billion in...

Company

Eli Lilly’s Q4 Sales Soar 45% to $13.53B on Strength of GLP-1 Drugs

Fineline Cube Feb 7, 2025

Eli Lilly & Co. (NYSE: LLY) reported a robust finish to 2024, with Q4 revenues...

Company

GSK Reports 7% Full-Year Sales Growth in 2024, Driven by Specialty Medicines

Fineline Cube Feb 6, 2025

UK-based pharmaceutical giant GSK plc (NYSE: GSK) released its Q4 and full-year 2024 financial results,...

Company

MSD Reports Strong Global Sales Growth in 2024, Despite China Challenges

Fineline Cube Feb 6, 2025

US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) released its Q4 2024 financial report,...

Company

Amgen Reports Strong Q4 and Full-Year 2024 Sales Growth

Fineline Cube Feb 6, 2025

Amgen (NASDAQ: AMGN) released its Q4 2024 financial results this week, reporting USD 33.42 billion...

Company

Novo Nordisk Reports Soaring Global Sales in 2024, Driven by Diabetes and Obesity Care

Fineline Cube Feb 6, 2025

Denmark’s Novo Nordisk (CPH: NOVO-B) reported this week that its global sales during 2024 reached...

Company Drug

Astellas Pharma Submits NDA for Avacincaptad Pegol in Japan for Geographic Atrophy

Fineline Cube Feb 6, 2025

Japan-based major Astellas Pharma (TYO: 4503) announced that it has submitted a New Drug Application...

Company Drug

Roche’s Susvimo Approved by FDA for Diabetic Macular Edema

Fineline Cube Feb 6, 2025

Swiss pharmaceutical giant Roche (SWX: ROG) announced that it has received approval from the US...

Company Drug

FDA Approves Enhertu for HER2-Low and HER2-UltraLow Breast Cancer

Fineline Cube Feb 6, 2025

The US Food and Drug Administration (FDA) has approved Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody...

Company Deals

Immunophage Partners with GoBroad Cancer Hospital for IPG1094 Phase II Study

Fineline Cube Feb 6, 2025

Nanjing-headquartered Immunophage Biotech Co., Ltd., a targeted therapy developer with operations in China, Australia, and...

Company Drug

Betta Pharmaceuticals Gains NMPA Approval for BPI-452080 Clinical Study

Fineline Cube Feb 6, 2025

China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) announced that it has received approval from the...

Company Drug

Haisco’s HSK39004 Gains NMPA Approval for COPD Clinical Trials

Fineline Cube Feb 6, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that it has received clinical trial...

Company Medical Device

Sino Medical Sciences’ NC Rockstar Catheter Gains MDA Approval in Malaysia

Fineline Cube Feb 6, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that it has received marketing approval...

Company Deals

Henan Lingrui to Acquire Yingu Pharma for RMB 704 Million

Fineline Cube Feb 6, 2025

China’s Henan Lingrui Pharmaceutical Co., Ltd. (SHA: 600285) announced plans to acquire a 90% ownership...

Posts pagination

1 … 222 223 224 … 670

Recent updates

  • Zai Lab Announces Executive Leadership Reshuffle as COO Josh Smiley Steps Down After Nearly Four Years
  • Allergan Aesthetics Secures CHMP Positive Opinion for Boey (TrenibotulinumtoxinE) in Glabellar Lines Treatment Across European Economic Area
  • Lupeng Pharma Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Fourth-Gen BTK Inhibitor Rocbrutinib vs. Pirtobrutinib
  • Eli Lilly’s Retatrutide Delivers Breakthrough Weight Loss Results in Phase 3 TRIUMPH-1 Trial for Obesity Treatment
  • Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Zai Lab Announces Executive Leadership Reshuffle as COO Josh Smiley Steps Down After Nearly Four Years

Company Drug

Allergan Aesthetics Secures CHMP Positive Opinion for Boey (TrenibotulinumtoxinE) in Glabellar Lines Treatment Across European Economic Area

Company Drug

Lupeng Pharma Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Fourth-Gen BTK Inhibitor Rocbrutinib vs. Pirtobrutinib

Company Drug

Eli Lilly’s Retatrutide Delivers Breakthrough Weight Loss Results in Phase 3 TRIUMPH-1 Trial for Obesity Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.